| Sarah Elizabeth Stafford, BPHARM | |
|
187 Niblick Rd, Paso Robles, CA 93446-4845 | |
| (805) 238-2947 | |
| (805) 238-3251 |
| Full Name | Sarah Elizabeth Stafford |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 187 Niblick Rd, Paso Robles, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154842714 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 59104 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Elizabeth Stafford, BPHARM 187 Niblick Rd, Paso Robles, CA 93446-4845 Ph: (805) 238-2947 | Sarah Elizabeth Stafford, BPHARM 187 Niblick Rd, Paso Robles, CA 93446-4845 Ph: (805) 238-2947 |
News Archive
Researchers from the University of Miami (UM) and the University of Heidelberg in Germany have developed a mathematical model to understand and predict the progress of a tumor, from its early stages to metastasis, in hopes of creating highly personalized treatment strategies for patients who have cancer. The findings are published in Nature's new online journal Scientific Reports.
Unibased Systems Architecture, Inc. (Unibased) announced the availability of the integration of its award-winning ForSite2020 solution suite with Microsoft Outlook 2010 for healthcare scheduling and resource management.
Joslin Diabetes Center (Joslin), the world-renowned leader in diabetes research and clinical care, and Diabetica Research Solutions, Inc. (DRSI), makers of drsi™ ReStore! Energy, the only energy and hydration formula specifically designed for the needs of people with diabetes, today announced they will work together to support diabetes causes and programs to which they are deeply committed, and help to educate others and raise awareness about diabetes, its causes and solutions, throughout the world.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
› Verified 9 days ago
Mrs. Maria C De Nysschen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2424 Spring St, Paso Robles, CA 93446 Phone: 805-239-3208 Fax: 805-239-1878 | |
Abigail Victoria Joy, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 187 Niblick Rd, Paso Robles, CA 93446 Phone: 805-238-2947 | |
Ms. Minakshi Gurbhele, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 187 Niblick Rd, Paso Robles, CA 93446 Phone: 805-238-2947 | |
David Bircher, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 187 Niblick Rd, Paso Robles, CA 93446 Phone: 805-238-2947 Fax: 805-238-3251 | |
Kellie Jones, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2424 Spring St, Paso Robles, CA 93446 Phone: 805-239-3208 Fax: 805-239-1878 | |
Stuart Wensil, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 189 Niblick Rd, Paso Robles, CA 93446 Phone: 805-237-1803 Fax: 805-237-8768 |